Vir Biotechnology, Inc.
VIRDrugs in Pipeline
10
Phase 3 Programs
4
Upcoming Catalysts
8
Next Catalyst
Nov 15, 2026
33wMarket Overview
Stock performance and key metrics
8 upcoming, 2 past
Tobevibart
Viral Hepatitis
Elebsiran
Viral Hepatitis
VIR-7831 (sotrovimab)
Covid19
Bulevirtide
Viral Hepatitis
NRTI
Hepatitis D, Chronic
VIR-2218
Hepatitis B, Chronic
pegylated interferon-alfa 2a
Chronic Hepatitis B
VIR-5818
Locally Advanced or Metastatic HER2-Expressing Cancers
Sotrovimab (Gen1)
Covid19
VIR-3434
Hepatitis B, Chronic
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Tobevibart | Phase 3 | Viral Hepatitis | - | - |
Elebsiran | Phase 3 | Viral Hepatitis | - | - |
VIR-7831 (sotrovimab) | Phase 3 | Covid19 | - | - |
Bulevirtide | Phase 3 | Viral Hepatitis | - | - |
NRTI | Phase 2 | Hepatitis D, Chronic | - | - |
VIR-2218 | Phase 2 | Hepatitis B, Chronic | - | - |
pegylated interferon-alfa 2a | Phase 2 | Chronic Hepatitis B | - | - |
VIR-5818 | Phase 2 | Locally Advanced or Metastatic HER2-Expressing Cancers | - | - |
Sotrovimab (Gen1) | Phase 2 | Covid19 | - | - |
VIR-3434 | Phase 2 | Hepatitis B, Chronic | - | - |
Viral Hepatitis
3 drugs in this indication
Covid19
2 drugs in this indication
Chronic Hepatitis B
2 drugs in this indication
Hepatitis B, Chronic
2 drugs in this indication
Hepatitis D, Chronic
1 drug in this indication
Locally Advanced or Metastatic HER2-Expressing Cancers
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)